Continuous Glucose Monitor (CGM) Sensor Fabrication | DSR
Technology & Innovation

Continuous Glucose Monitor (CGM) Sensor Fabrication

CGM sensor fabrication is harder than making disposable test strips, because a CGM sensor has to read accurately inside the body for days to weeks. Key fabrication pillars include:

1. Geometry: A split between Planar (screen-printed on flexible polymer, e.g., Abbott) and Wire-based (Pt-Ir wire with dip-coatings, e.g., Dexcom) architectures.

2. Chemistry: There is no single industry chemistry. Dexcom sensors and Medtronic's own MiniMed sensors use glucose oxidase with hydrogen peroxide detection; Abbott uses its "Wired Enzyme" technology (an osmium redox mediator), which reduces sensitivity to changing oxygen levels; Eversense measures glucose optically, by fluorescence.

3. Membrane Engineering: Multi-layer membranes limit glucose flux to keep the signal proportional to glucose, help block electrochemical interferents (like acetaminophen), and must cope with the Foreign Body Response to maintain sensitivity over time.

4. Factory Calibration: Tight control of membrane thickness and electrode area lets sensors such as the Dexcom G7 and FreeStyle Libre skip user fingerstick calibration, but not every CGM does: the Eversense 365 still requires fingerstick calibrations.

Diabetic Supply Rescue Editorial Team
4 min read
Last updated: October 09, 2026
Advanced
9 glossary terms
10 citations

Introduction to CGM Sensor Fabrication

A test strip works once, for a few seconds, on a drop of blood. A CGM sensor has to keep working for days to weeks in the fluid under the skin, while the body treats it as a foreign object [1].

That is why fabrication carries so much weight. Abbott's sensor engineers write that the sensing area is smaller than 1 mm² and the glucose-limiting membrane is typically thinner than 100 µm, so small differences between sensors show up as differences in the reading [1].

Key Fabrication Pillars

We grouped what we read into four pillars. The second one, chemistry, is where manufacturers differ most:

  • Geometry: Abbott and Dexcom build their sensors in different shapes, planar and wire-based.

Abbott uses screen-printed planar sensors on flexible polymers, while Dexcom uses Pt-Ir wire with dip-coatings. FDA records confirm the wire: the FDA's decision summary for the Dexcom G6 warns that a broken sensor wire could stay under the skin [4]. Dexcom stopped manufacturing the G6 after July 1, 2026, and is moving users to its G7 sensors [5].

  • Chemistry: There is no single CGM industry chemistry. As of October 2026, the sensors we looked at use one of three designs.
  • Dexcom: the enzyme glucose oxidase reacts with glucose and produces hydrogen peroxide, and the electrode turns that peroxide into a current proportional to glucose. The FDA describes the Dexcom G7 this way [3].
  • MiniMed: the sensors Medtronic developed, such as the earlier Enlite sensor, are also glucose oxidase sensors [6], and the classic form of that design measures hydrogen peroxide at a platinum electrode [7]. MiniMed's 780G system now also works with the Instinct sensor, which Abbott makes [10].
  • Abbott: "Wired Enzyme" technology. Glucose oxidase still does the first step, but an osmium complex carries electrons from the enzyme to the electrode [1]. Here's what surprised us: the chemistry doesn't remove oxygen effects entirely. Its developers described "reduced susceptibility" to changing oxygen levels in the body, plus a smaller response to common interfering substances [2], which Abbott credits to running the electrode at a low electrical potential [1]. The FDA's summary for the FreeStyle Libre 2 and 3 systems also describes the enzyme handing electrons to an electrode [8].
  • Eversense: no enzyme at all. The Eversense 365 implant measures glucose optically. Glucose binds reversibly to a fluorescent indicator on the sensor, and the sensor reads the change in light [9].
  • Membrane Engineering: Multi-layer membranes limit how fast glucose reaches the enzyme. Abbott's engineers rank that flux-limiting membrane, along with the enzyme layer, as the most critical part of the sensor [1]. The layers also help block electrochemical interferents; Dexcom, for example, designed the G6 sensor to reduce the acetaminophen interference seen in earlier Dexcom systems [4]. Finally, the design has to minimize the Foreign Body Response, or keep it from disturbing the signal, so sensitivity stays stable through the wear period [1].
  • Factory Calibration: In factory calibration, the calibration step happens during manufacturing under laboratory conditions, and each sensor lot gets a code that converts the sensor's current into a glucose value [1]. That only works if every sensor in a lot behaves alike, which depends on precise control of electrode area and membrane thickness [1]. Abbott's FreeStyle Libre sensors were the first commercially available CGM sensors calibrated this way [1]. The Dexcom G7 is factory calibrated, with manual calibration optional [3]. Not every CGM skips fingersticks, though. The Eversense 365 needs four fingerstick calibrations after its 24-hour warm-up, then one a day through day 13, then one a week [9].

Conclusion

These choices explain why CGMs that all report a glucose number can behave differently in the body. A Dexcom, an Abbott and an Eversense sensor rely on peroxide detection, an osmium mediator and fluorescence respectively [3] [1] [9]. One thing we could not pin down in FDA summaries or the papers we read: the exact electrode materials and coating steps each company uses.

References

  1. Hoss U, Budiman ES. Factory-Calibrated Continuous Glucose Sensors: The Science Behind the Technology. Diabetes Technol Ther. 2017;19(S2):S44-S50Source
  2. Feldman B, Brazg R, Schwartz S, Weinstein R. A continuous glucose sensor based on wired enzyme technology: results from a 3-day trial in patients with type 1 diabetes. Diabetes Technol Ther. 2003;5(5):769-779Source
  3. FDA 510(k) Decision Summary K213919: Dexcom G7 Continuous Glucose Monitoring SystemSource
  4. FDA De Novo Decision Summary DEN170088: Dexcom G6 Continuous Glucose Monitoring SystemSource
  5. Dexcom: Dexcom G6 transition (end of manufacturing after July 1, 2026)Source
  6. Sharifi A, Varsavsky A, Ulloa J, et al. Redundancy in Glucose Sensing: Enhanced Accuracy and Reliability of an Electrochemical Redundant Sensor for Continuous Glucose Monitoring. J Diabetes Sci Technol. 2016;10(3):669-678Source
  7. Cappon G, Vettoretti M, Sparacino G, Facchinetti A. Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications. Diabetes Metab J. 2019;43(4):383-397Source
  8. FDA 510(k) Decision Summary K233537: FreeStyle Libre 2 and FreeStyle Libre 3 systemsSource
  9. FDA 510(k) Decision Summary K241335: Eversense 365 CGM SystemSource
  10. MiniMed news release: U.S. commercial launch of the MiniMed 780G system with the Instinct sensor, made by AbbottSource

Was this article helpful?

Explore More Topics

Continue your research with related categories